The 2α and 2β-hydroxy as well as the 2α(3'-hydroxypropoxy)- and 2β(3'-hydroxypropoxy)- and 2α(benzyloxy)- analogs of 19-nor-1α,25-dihydroxyvitamin D₃ are disclosed. The two 2-hydroxy analogs showed in vivo calcium transport with little or no bone calcium mobilization; the 2β-more than the 2α- analog. Both analogs induced differentiation of malignant cells. The two analogs thus show promise in the treatment of osteoporosis. The 2α-hydroxypropoxy analog showed a selective activity profile, combining high potency in inducing differentiation of malignant cells with very low or no bone calcification activity, a possible use in the treatment of malignancies.
本研究公开了 19-去甲-1α,25-二羟基
维生素 D₃的 2α、2β-羟基以及 2α(3'-羟基丙氧基)- 和 2β(3'-羟基丙氧基)- 和 2α(苄氧基)- 类似物。这两种 2- 羟基类似物在体内显示出
钙转运作用,但几乎没有骨
钙动员作用;2β- 类似物的骨
钙动员作用大于 2α- 类似物。这两种类似物都能诱导恶性细胞分化。因此,这两种类似物有望用于治疗骨质疏松症。2α-羟基丙氧基类似物显示出一种选择性的活性特征,既具有诱导恶性细胞分化的高效力,又具有极低或无骨
钙化活性,可用于治疗恶性肿瘤。